GB201704714D0 - Pharmaceutical compounds - Google Patents
Pharmaceutical compoundsInfo
- Publication number
- GB201704714D0 GB201704714D0 GBGB1704714.3A GB201704714A GB201704714D0 GB 201704714 D0 GB201704714 D0 GB 201704714D0 GB 201704714 A GB201704714 A GB 201704714A GB 201704714 D0 GB201704714 D0 GB 201704714D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- pharmaceutical compounds
- pharmaceutical
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Priority Applications (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1704714.3A GB201704714D0 (en) | 2017-03-24 | 2017-03-24 | Pharmaceutical compounds |
| CA3057415A CA3057415A1 (en) | 2017-03-24 | 2018-03-26 | Tetrahydro-benzo[d]azepine derivatives as gpr120 modulators |
| BR112019019868A BR112019019868A2 (pt) | 2017-03-24 | 2018-03-26 | derivados de tetra-hidro-benzo[d]azepina como moduladores gpr120 |
| KR1020197031368A KR102636166B1 (ko) | 2017-03-24 | 2018-03-26 | GPR120 조절제로서의 테트라하이드로-벤조[d]아제핀 유도체 |
| JP2020501850A JP7099672B2 (ja) | 2017-03-24 | 2018-03-26 | 医薬化合物 |
| US16/496,786 US11220483B2 (en) | 2017-03-24 | 2018-03-26 | Tetrahydro-benzo[d]azepine derivatives as GPR120 modulators |
| EP18715236.8A EP3601229B1 (en) | 2017-03-24 | 2018-03-26 | Tetrahydro-benzo[d]azepine derivatives as gpr120 modulators |
| AU2018238102A AU2018238102B2 (en) | 2017-03-24 | 2018-03-26 | Tetrahydro-benzo(d)azepine derivatives as GPR120 modulators |
| CN201880033700.7A CN110891938B (zh) | 2017-03-24 | 2018-03-26 | 四氢-苯并[d]氮杂环庚熳衍生物作为gpr120调节剂 |
| MX2019011314A MX394818B (es) | 2017-03-24 | 2018-03-26 | Derivados de tetrahidro-benzo[d]azepina como moduladores de gpr120. |
| RU2019133659A RU2776801C2 (ru) | 2017-03-24 | 2018-03-26 | Производные тетрагидробензо[d]азапена в качестве модуляторов as gpr120 |
| PCT/GB2018/000047 WO2018172727A1 (en) | 2017-03-24 | 2018-03-26 | Tetrahydro-benzo[d]azepine derivatives as gpr120 modulators |
| ZA2019/06873A ZA201906873B (en) | 2017-03-24 | 2019-10-18 | Tetrahydro-benzo[d]azepine derivatives as gpr120 modulators |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1704714.3A GB201704714D0 (en) | 2017-03-24 | 2017-03-24 | Pharmaceutical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201704714D0 true GB201704714D0 (en) | 2017-05-10 |
Family
ID=58687800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB1704714.3A Ceased GB201704714D0 (en) | 2017-03-24 | 2017-03-24 | Pharmaceutical compounds |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11220483B2 (enExample) |
| EP (1) | EP3601229B1 (enExample) |
| JP (1) | JP7099672B2 (enExample) |
| KR (1) | KR102636166B1 (enExample) |
| CN (1) | CN110891938B (enExample) |
| AU (1) | AU2018238102B2 (enExample) |
| BR (1) | BR112019019868A2 (enExample) |
| CA (1) | CA3057415A1 (enExample) |
| GB (1) | GB201704714D0 (enExample) |
| MX (1) | MX394818B (enExample) |
| WO (1) | WO2018172727A1 (enExample) |
| ZA (1) | ZA201906873B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111712494A (zh) | 2018-02-13 | 2020-09-25 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| EP4600247A3 (en) | 2018-04-19 | 2025-11-19 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| KR20230159715A (ko) | 2018-07-13 | 2023-11-21 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| AU2019366355B2 (en) | 2018-10-24 | 2022-10-13 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| WO2021071837A1 (en) | 2019-10-07 | 2021-04-15 | Kallyope, Inc. | Gpr119 agonists |
| BR112022017039A2 (pt) | 2020-02-28 | 2022-11-16 | Kallyope Inc | Agonistas de gpr40 |
| JP2023526625A (ja) | 2020-05-19 | 2023-06-22 | キャリーオペ，インク． | Ａｍｐｋアクチベーター |
| CN116390925A (zh) | 2020-06-26 | 2023-07-04 | 卡尔优普公司 | Ampk活化剂 |
| CN114163426B (zh) * | 2020-09-10 | 2024-03-19 | 上海爱博医药科技有限公司 | 苯并含氧杂环类化合物及其医药应用 |
| US12454511B2 (en) * | 2020-10-08 | 2025-10-28 | Eli Lilly And Company | 6-methoxy-3,4-dihydro-1H-isoquinolin compounds |
| CN114671827B (zh) * | 2020-12-24 | 2024-09-20 | 杭州百新生物医药科技有限公司 | 邻苯甲酰磺酰亚胺类衍生物及其应用 |
| KR102605163B1 (ko) * | 2021-06-01 | 2023-11-23 | 연세대학교 산학협력단 | 뇌암의 예방 또는 치료용 조성물 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005282721A1 (en) * | 2004-09-03 | 2006-03-16 | Memory Pharmaceuticals Corporation | 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms |
| EP1940819A1 (en) | 2005-08-16 | 2008-07-09 | Memory Pharmaceuticals Corporation | Phosphodiesterase 10 inhibitors |
| RU2008135126A (ru) * | 2006-01-30 | 2010-03-10 | Айрм Ллк (Bm) | Полициклические производные тетрагидроизохинолина и содержащие их композиции в качестве модуляторов ppar |
| EP2077846B1 (en) * | 2006-11-02 | 2011-10-12 | Piramal Life Sciences Limited | Benzoxazepine compounds, their preparation and use |
| BRPI0807637A2 (pt) * | 2007-02-22 | 2014-06-03 | Irm Llc | Derivados de tiazol como moduladores de receptores acoplados à proteína g |
| CA2725316A1 (en) * | 2008-06-02 | 2009-12-10 | Banyu Pharmaceutical Co., Ltd. | Novel isoxazole derivative |
| WO2013019682A1 (en) | 2011-07-29 | 2013-02-07 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
| WO2016022448A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2016022446A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [5,6]-fused bicyclic antidiabetic compounds |
| CN115925679A (zh) * | 2014-12-24 | 2023-04-07 | 株式会社Lg化学 | 作为gpr120激动剂的联芳基衍生物 |
| WO2017201683A1 (en) * | 2016-05-25 | 2017-11-30 | Merck Sharp & Dohme Corp. | Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists |
-
2017
- 2017-03-24 GB GBGB1704714.3A patent/GB201704714D0/en not_active Ceased
-
2018
- 2018-03-26 EP EP18715236.8A patent/EP3601229B1/en active Active
- 2018-03-26 MX MX2019011314A patent/MX394818B/es unknown
- 2018-03-26 KR KR1020197031368A patent/KR102636166B1/ko active Active
- 2018-03-26 JP JP2020501850A patent/JP7099672B2/ja active Active
- 2018-03-26 CN CN201880033700.7A patent/CN110891938B/zh active Active
- 2018-03-26 US US16/496,786 patent/US11220483B2/en active Active
- 2018-03-26 BR BR112019019868A patent/BR112019019868A2/pt not_active Application Discontinuation
- 2018-03-26 CA CA3057415A patent/CA3057415A1/en active Pending
- 2018-03-26 WO PCT/GB2018/000047 patent/WO2018172727A1/en not_active Ceased
- 2018-03-26 AU AU2018238102A patent/AU2018238102B2/en active Active
-
2019
- 2019-10-18 ZA ZA2019/06873A patent/ZA201906873B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019011314A (es) | 2020-01-27 |
| US20200317619A1 (en) | 2020-10-08 |
| JP2020515636A (ja) | 2020-05-28 |
| CN110891938B (zh) | 2023-10-31 |
| AU2018238102A2 (en) | 2019-11-07 |
| RU2019133659A (ru) | 2021-04-26 |
| EP3601229A1 (en) | 2020-02-05 |
| CN110891938A (zh) | 2020-03-17 |
| AU2018238102A1 (en) | 2019-10-31 |
| WO2018172727A1 (en) | 2018-09-27 |
| BR112019019868A2 (pt) | 2020-04-22 |
| KR20190140936A (ko) | 2019-12-20 |
| RU2019133659A3 (enExample) | 2021-07-16 |
| JP7099672B2 (ja) | 2022-07-12 |
| EP3601229B1 (en) | 2024-11-06 |
| CA3057415A1 (en) | 2018-09-27 |
| US11220483B2 (en) | 2022-01-11 |
| KR102636166B1 (ko) | 2024-02-13 |
| AU2018238102B2 (en) | 2021-11-04 |
| ZA201906873B (en) | 2022-03-30 |
| MX394818B (es) | 2025-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL266017A (en) | Pharmaceutical compounds | |
| IL258213B (en) | Pharmaceutical compounds | |
| GB201612092D0 (en) | Pharmaceutical compounds | |
| GB201617758D0 (en) | Pharmaceutical compounds | |
| GB201504675D0 (en) | Pharmaceutical compounds | |
| ZA201900540B (en) | Pharmaceutical compounds | |
| GB201506658D0 (en) | Pharmaceutical compounds | |
| EP3638658C0 (en) | PHARMACEUTICAL COMPOUNDS | |
| GB201519352D0 (en) | Pharmaceutical compounds | |
| GB201506660D0 (en) | Pharmaceutical compounds | |
| GB201617454D0 (en) | Pharmaceutical compounds | |
| IL258246A (en) | Pharmaceutical compounds | |
| GB201704714D0 (en) | Pharmaceutical compounds | |
| GB201704965D0 (en) | Pharmaceutical compounds | |
| GB201703881D0 (en) | Pharmaceutical compounds | |
| GB201617627D0 (en) | Pharmaceutical compounds | |
| GB201612095D0 (en) | Pharmaceutical compounds | |
| GB201506933D0 (en) | Pharmaceutical compounds | |
| GB201502567D0 (en) | Pharmaceutical compounds | |
| GB201706806D0 (en) | Pharmaceutical compounds | |
| GB201711704D0 (en) | Pharmaceutical compounds | |
| SMT202200092T1 (it) | Composti farmaceutici | |
| GB201704966D0 (en) | Pharmaceutical compounds | |
| GB201617871D0 (en) | Pharmaceutical compounds | |
| GB201615912D0 (en) | Pharmaceutical compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |